These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16819578)

  • 1. Metabolic and immunologic derangements in cardiac cachexia: where to from here?
    Strassburg S; Anker SD
    Heart Fail Rev; 2006 Mar; 11(1):57-64. PubMed ID: 16819578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac cachexia: a systematic overview.
    von Haehling S; Lainscak M; Springer J; Anker SD
    Pharmacol Ther; 2009 Mar; 121(3):227-52. PubMed ID: 19061914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
    Springer J; Tschirner A; Haghikia A; von Haehling S; Lal H; Grzesiak A; Kaschina E; Palus S; Pötsch M; von Websky K; Hocher B; Latouche C; Jaisser F; Morawietz L; Coats AJ; Beadle J; Argiles JM; Thum T; Földes G; Doehner W; Hilfiker-Kleiner D; Force T; Anker SD
    Eur Heart J; 2014 Apr; 35(14):932-41. PubMed ID: 23990596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological management of cardiac cachexia: a review of potential therapy options.
    Rolfe M; Kamel A; Ahmed MM; Kramer J
    Heart Fail Rev; 2019 Sep; 24(5):617-623. PubMed ID: 30923991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone in heart failure--a revived role for an old drug.
    Bradley C
    Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches.
    Akashi YJ; Springer J; Anker SD
    Curr Heart Fail Rep; 2005 Dec; 2(4):198-203. PubMed ID: 16332313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone, a new appreciation of its role in heart failure.
    Cha AJ; Malecha SE; Judge KW
    Pharmacotherapy; 2000 Sep; 20(9):1107-15. PubMed ID: 10999504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia.
    Anker SD; Rauchhaus M
    Curr Opin Cardiol; 1999 May; 14(3):211-6. PubMed ID: 10358792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure.
    von Haehling S; Doehner W; Anker SD
    Cardiovasc Res; 2007 Jan; 73(2):298-309. PubMed ID: 17034772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heart failure and cachexia].
    Tabet JY; Meurin P; Ben Driss A; Logeart D; Héliès-Toussaint C; Tartière JM; Cohen-Solal A; Grynberg A; Bourdel-Marchasson I
    Arch Mal Coeur Vaiss; 2006 Dec; 99(12):1203-9. PubMed ID: 18942522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
    Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
    Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
    Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
    Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic heart failure and cachexia: role of endocrine system].
    Dei Cas A; Muoio A; Zavaroni I
    Minerva Cardioangiol; 2011 Dec; 59(6):601-12. PubMed ID: 19946251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone in congestive heart failure.
    Soberman JE; Weber KT
    Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
    Struthers AD
    Br J Clin Pharmacol; 1999 May; 47(5):479-82. PubMed ID: 10336570
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of aldosterone antagonists in the cardiovascular diseases].
    Trzaska E; Gumułka W; Makulska-Nowak HE
    Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of a selective aldosterone blocker in mice with chronic heart failure.
    Wang D; Liu YH; Yang XP; Rhaleb NE; Xu J; Peterson E; Rudolph AE; Carretero OA
    J Card Fail; 2004 Feb; 10(1):67-73. PubMed ID: 14966777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.